Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Programming Cells to Target Specific Tissues May Enable More Effective Cell-Based Therapies

By BiotechDaily International staff writers
Posted on 08 Nov 2011
Stem cell therapies hold huge potential to tackle some of the most devastating disorders, diseases, and tissue defects worldwide. However, the inability to target cells to tissues of interest poses a considerable hurdle to effective cell therapy. To address this obstacle, researchers have devised a platform approach to incorporate chemically homing receptors onto the surface of cells. This simple application has the potential to improve the effectiveness of many types of cell therapies by increasing the concentrations of cells at target locations in the body.

The study’s findings were published online in the journal Blood on October 27, 2011. For this new platform, researchers modified the surface of cells to include receptors that act as a homing device. “The central hypothesis of our work is that the ability of cells to home to specific tissues can be enhanced, without otherwise altering cell function,” said corresponding author Jeffrey M. Karp, PhD, codirector of the Regenerative Therapeutics Center at Brigham and Women’s Hospital (BWH; Boston, MA, USA), and a principal faculty member of the Harvard Stem Cell Institute. “By knowing the ‘zip code’ [US postal code] of the blood vessels in specific tissues, we can program the ‘address’ onto the surface of the cells to potentially target them with high efficiencies.”

Whereas traditional cell therapies that include local administration of cells can be useful, they are typically more invasive with limited potential for multiple doses. “You can imagine, that when the targeted tissue is cardiac muscle, for example to treat heart attacks or heart failure, injecting the cells directly into the heart can be an invasive procedure and typically this approach can only be performed once,” said Dr. Karp, also an assistant professor at Harvard Medical School (Boston, MA, USA) and affiliate faculty Harvard-Massachusetts Institute of Technology (MIT) Division of Health Sciences and Technology (Cambridge, MA, USA).

Using the platform the researchers created, the cells are prepared to travel directly to the area of interest after being injected through a common and much less invasive intravenous infusion technique. “These engineered cells may also be more effective because multiple doses can be administered,” stated Debanjan Sarkar, PhD, previously a postdoctoral fellow in Dr. Karp’s lab and now an assistant professor of Biomedical Engineering at the State University of New York, University at Buffalo (NY, USA).

“The necessity for a more effective delivery approach stems from the potential diseases cell therapy may address,” said Dr. Karp, noting that the approach can be used to systemically target bone producing cells to the bone marrow to treat osteoporosis, cardiomyocytes to the heart to treat ischemic tissue, neural stem cells to the brain to treat Parkinson’s disease, or endothelial progenitor cells to sites of peripheral vascular disease to promote formation of new blood vessels.

The researchers concluded that, as the determination of the processes of cell trafficking grows, the capability to improve homing to specific tissues through engineered techniques should considerably enhance cell therapy by reducing the invasiveness of local administration, allowing repeat dosing, and potentially reducing the number of cells needed to achieve a therapeutic effect, in the end providing better outcomes for patients.

Related Links:
Brigham and Women’s Hospital





comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Differences in the structure of a small lung artery (top row) and heart cross section (lower row) of rodents without disease (far left column); with pulmonary hypertension (middle) and a diseased rodent treated with the HDL peptide (right). Note the much narrowed lung artery, and thick walls and larger chamber of the heart in the diseased animal and improvements with 4F peptide treatment (Photo courtesy of UCLA - University of California, Los Angeles).

Apolipoprotein A-1 Mimetic Peptide Reverses Pulmonary Hypertension in Rodent Models

A small peptide that mimics the activity of apolipoprotein A-1 (apo A-1), the main protein component of the high density lipoproteins (HDL), counteracted the effects of oxidized lipids and alleviated symptoms... Read more

Drug Discovery

view channel
Image: (Left) Neurons in brains from people with autism do not undergo normal pruning during childhood and adolescence. The images show representative neurons from unaffected brains (left) and brains from autistic patients (right); the spines on the neurons indicate the location of synapses (Photo courtesy of Guomei Tang, PhD and Mark S. Sonders, PhD, Columbia University Medical Center).

Autistic Youngsters Found to Have Too Many Brain Synapses

Autistic children and adolescents have been shown to have an excess of brain synapses, and this is due to a slowdown in the normal brain “trimming” process during development, according to new findings.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel

Important Immune Cell Regulators’ Response Identified

A new strategy could help accelerate laboratory research and the development of potential therapeutics, including vaccines. The technology may also be used to identify the genes that underlie tumor cell development. There are approximately 40,000 genes in each of the body’s cells, but functions for only approximately... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.